Edwards Lifesciences (EW) Revenue — Quarter Ended Sep 30, 2025
Revenue increased compared to the immediately preceding quarter and the same quarter one year earlier. The reported revenue direction is upward.
Key takeaway
Quarter ended Sep 30, 2025 · FY2025 Q3
Revenue increased compared to the immediately preceding quarter and the same quarter one year earlier. The reported revenue direction is upward.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$1.6B
Revenue reported for this quarter.
Quarter-over-quarter
+1.4%
Change from the immediately preceding quarter.
Year-over-year
+14.7%
Change from the comparable year-ago quarter.
Trailing four quarters
$5.9B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2024 | $1.4B | +9.4% |
| Mar 31, 2025 | $1.4B | +6.2% |
| Jun 30, 2025 | $1.5B | +11.9% |
| Sep 30, 2025 | $1.6B | +14.7% |
Revenue performance
The year-over-year revenue growth was larger than the sequential growth.
Quarterly comparison
Compared to the prior quarter, revenue rose; compared to the same quarter last year, the increase was greater.
What to watch
The filing includes forward-looking statements that are subject to risks and uncertainties.